Targeted Delivery of VP1 Antigen of Foot-and-mouth Disease Virus to M Cells Enhances the Antigen-specific Systemic and Mucosal Immune Response
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Application of vaccine materials through oral mucosal route confers great economical advantage in animal farming industry due to much less vaccination cost compared with that of injection-based vaccination. In particular, oral administration of recombinant protein antigen against foot-and- mouth disease virus (FMDV) is an ideal strategy because it is safe from FMDV transmission during vaccine production and can induce antigen-specific immune response in mucosal compartments, where FMDV infection has been initiated, which is hardly achievable through parenteral immunization. Given that effective delivery of vaccine materials into immune inductive sites is prerequisite for effective oral mucosal vaccination, M cell-targeting strategy is crucial in successful vaccination since M cells are main gateway for luminal antigen influx into mucosal lymphoid tissue. Here, we applied previously identified M cell-targeting ligand Co1 to VP1 of FMDV in order to test the possible oral mucosal vaccination against FMDV infection. M cell-targeting ligand Co1-conjugated VP1 interacted efficiently with M cells of Peyer’s patch. In addition, oral administration of ligand-conjugated VP1 enhanced the induction of VP1-specific IgG and IgA responses in systemic and mucosal compartments, respectively, in comparison with those from oral administration of VP1 alone. In addition, the enhanced VP1-specific immune response was found to be due to antigen-specific Th2-type cytokine production. Collectively, it is suggested that the M cell-targeting strategy could be applied to develop efficient oral mucosal vaccine against FMDV infection
Abstract
Application of vaccine materials through oral mucosal route confers great economical advantage in animal farming industry due to much less vaccination cost compared with that of injection-based vaccination. In particular, oral administration of recombinant protein antigen against foot-and- mouth disease virus (FMDV) is an ideal strategy because it is safe from FMDV transmission during vaccine production and can induce antigen-specific immune response in mucosal compartments, where FMDV infection has been initiated, which is hardly achievable through parenteral immunization. Given that effective delivery of vaccine materials into immune inductive sites is prerequisite for effective oral mucosal vaccination, M cell-targeting strategy is crucial in successful vaccination since M cells are main gateway for luminal antigen influx into mucosal lymphoid tissue. Here, we applied previously identified M cell-targeting ligand Co1 to VP1 of FMDV in order to test the possible oral mucosal vaccination against FMDV infection. M cell-targeting ligand Co1-conjugated VP1 interacted efficiently with M cells of Peyer’s patch. In addition, oral administration of ligand-conjugated VP1 enhanced the induction of VP1-specific IgG and IgA responses in systemic and mucosal compartments, respectively, in comparison with those from oral administration of VP1 alone. In addition, the enhanced VP1-specific immune response was found to be due to antigen-specific Th2-type cytokine production. Collectively, it is suggested that the M cell-targeting strategy could be applied to develop efficient oral mucosal vaccine against FMDV infection
참고문헌 (20)
- O'Donnell, V., "Analysis of foot-and-mouth disease virus internalization events in cultured cells", J. Virol, 79, pp.8506~8518 (2005)
- Rodriguez, L. L, "Foot and mouth disease virus vaccines", Vaccine, 27(Suppl 4), pp.D90~D94 (2009)
- Zhang, L. J., "Research in advance for FMD novel vaccines", Virol. J, 8, pp.268~ (2011)
- Cubillos, C., "Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide", J. Virol, 82, pp.7223~7230 (2008)
- Mestecky, J., "Oral immunization: an update", Curr. Opin. Gastroenterol, 24, pp.713~719 (2008)
- Pasetti, M. F., "Immunology of gut mucosal vaccines", Immunol. Rev, 239, pp.125~148 (2011)
- Brandtzaeg, P., "Mucosal immunity: induction, dissemination, and effector functions", Scand. J. Immunol, 70, pp.505~515 (2009)
- Holmgren, J., "Mucosal immunity and vaccines", Nat. Med, 11(4 Suppl), pp.S45~S53 (2005)
- Kim, S. H., "The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination", J. Immunol, 185, pp.5787~5795 (2010)
- Kim, S. H., "M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery", Eur. J. Immunol, 41, pp.3219~3229 (2011)
- Hase, K., "Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response", Nature, 462, pp.226~230 (2009)
- Cerutti, A., "Immunoglobulin responses at the mucosal interface", Annu. Rev. Immunol, 29, pp.273~293 (2011)
- Azizi, A., "Enhancing oral vaccine potency by targeting intestinal M cells", PLoS Pathog, 6, pp.e1001147~ (2010)
- 김새해, "Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination", Immune Network, 12(5), pp.165~175 (2012), 대한면역학회
- Hutber, A. M., "Foot-and-mouth disease: the question of implementing vaccinal control during an epidemic", Vet. J, 188, pp.18~23 (2011)
- Cerutti, A., "The regulation of IgA class switching", Nat. Rev. Immunol, 8, pp.421~434 (2008)
- Strugnell, R. A, "The role of secretory antibodies in infection immunity", Nat. Rev. Microbiol, 8, pp.656~667 (2010)
- Kaetzel, C. S., "The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA", Proc. Natl. Acad. Sci. U. S. A, 88, pp.8796~8800 (1991)
- Pabst, O., "New concepts in the generation and functions of IgA", Nat. Rev. Immunol, 12, pp.821~832 (2012)
- Schulz, O, "Antigen sampling in the small intestine", Trends. Immunol, 34, pp.155~161 (2013)